 |
|
Pulmonary Mucormycosis
The Last 30 Years
Francis Y. W. Lee, MD;
Sherif B. Mossad, MD;
Karim A. Adal, MD, MS
Arch Intern Med. 1999;159:1301-1309.
Pulmonary mucormycosis is relatively uncommon but an important opportunistic fungal infection in immunocompromised persons. The literature on the subject is sparse. We describe a recent case and review the literature to delineate the clinical characteristics of this infection. We searched the MEDLINE database for articles published in the English-language literature since 1970 and carefully analyzed 87 cases. The main risk factors were diabetes mellitus, hematologic cancers, renal insufficiency, and organ transplantation. Several patients had no apparent immune compromise. There was a predilection for involvement of the upper lobes. Air crescent signs on chest x-ray films were predictors of pulmonary hemorrhage and death from hemoptysis. Fiberoptic bronchoscopy was a useful diagnostic method, and histopathologic examination was more sensitive than fungal cultures. The overall survival rate was 44%. Patients treated with a combined medical-surgical approach had a better outcome than patients who did not undergo surgery. Thus, this relatively rare but often fatal disease should be suspected in immunocompromised patients who fail to respond to antibacterial therapy. Early recognition and aggressive management are warranted to maximize chances for cure. Optimal therapy requires systemic antifungal therapy, surgical resection, and, when possible, control of the patient's underlying disease.
From the Division of Internal Medicine (Dr Lee), Department of Infectious Disease (Drs Mossad and Adal), Cleveland Clinic Foundation, Cleveland, Ohio.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(12):1378.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cavitary Pulmonary Disease
Gadkowski and Stout
Clin. Microbiol. Rev. 2008;21:305-333.
ABSTRACT
| FULL TEXT
A 40-Year-Old Man With Neutropenic Fever and Lobar Consolidation
Holley et al.
Chest 2008;133:816-819.
FULL TEXT
Fatal post-traumatic zygomycosis in an immunocompetent young patient
Kontogiorgi et al.
J Med Microbiol 2007;56:1243-1245.
ABSTRACT
| FULL TEXT
Posaconazole as Salvage Therapy for Zygomycosis
Greenberg et al.
Antimicrob. Agents Chemother. 2006;50:126-133.
ABSTRACT
| FULL TEXT
Zygomycosis: An emerging fungal infection
Brown
Am J Health Syst Pharm 2005;62:2593-2596.
ABSTRACT
| FULL TEXT
Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management
Spellberg et al.
Clin. Microbiol. Rev. 2005;18:556-569.
ABSTRACT
| FULL TEXT
A Neutropenic Patient With Rapidly Progressive Lung Lesion
Pauls et al.
Chest 2004;126:1364-1367.
FULL TEXT
Pulmonary mucormycosis in a patient with chronic obstructive pulmonary disease: Diagnosis by fine needle aspiration cytology
Benekli et al.
J. Thorac. Cardiovasc. Surg. 2004;127:588-589.
FULL TEXT
In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents
Dannaoui et al.
Antimicrob. Agents Chemother. 2002;46:2708-2711.
ABSTRACT
| FULL TEXT
Persistent cavitations in pulmonary mucormycosis after apparently successful amphotericin B
Donado-Una et al.
Eur. J. Cardiothorac. Surg. 2002;21:940-942.
ABSTRACT
| FULL TEXT
Diabetes and rapidly advancing pneumonia
Postgrad. Med. J. 2001;77:736c-736.
FULL TEXT
Pulmonary Mucormycosis
Hong et al.
Asian Cardiovasc. Thorac. Ann. 2001;9:146-149.
ABSTRACT
| FULL TEXT
|
